NCT06099080View on ClinicalTrials.gov

A Trial to Study the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Dermatosis Papulosa Nigra (DPN)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

November 7, 2023

Primary Completion Date

July 25, 2024

Study Completion Date

July 25, 2024

Conditions
Dermatosis Papulosa Nigra
Interventions
DRUG

SM-020 gel 1.0%

Subjects will apply the investigational product twice daily for 4 consecutive weeks. Subjects will be followed for 12 weeks post final application for a total of approximately 16 weeks of required participation in the study.

Trial Locations (1)

90036

Vitiligo & Pigmentation Institute of Southern California, Los Angeles

Sponsors

Lead Sponsor

DermBiont, Inc.
All Listed Sponsors
lead

DermBiont, Inc.

INDUSTRY